Nektar Therapeutics (NKTR) vs Recursion Pharmaceuticals, Inc. (RXRX)
Nektar Therapeutics and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Nektar Therapeutics and Recursion Pharmaceuticals, Inc. are of similar size ($2.1B and $2.1B). Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −15.1% against −27.2%. Nektar Therapeutics has the higher net margin (−287.8% vs −945.9%) and the higher return on invested capital (−40.2% vs −92.2%). Across the 18 metrics below, Nektar Therapeutics leads on 13 and Recursion Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | NKTR | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 3.48% | 65.16% |
| Operating margin | (257.80%) | (991.72%) | 0.00% |
| Net margin | (287.84%) | (945.92%) | 0.00% |
| Free cash flow margin | (428.72%) | (645.82%) | 0.00% |
| Return on equity | (35.75%) | (56.58%) | (57.72%) |
| Return on assets | (24.12%) | (41.26%) | (49.22%) |
| Return on invested capital | (40.20%) | (92.22%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack